MX2022003507A - Modulos de union que comprenden dominios ehd2 modificados. - Google Patents

Modulos de union que comprenden dominios ehd2 modificados.

Info

Publication number
MX2022003507A
MX2022003507A MX2022003507A MX2022003507A MX2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A MX 2022003507 A MX2022003507 A MX 2022003507A
Authority
MX
Mexico
Prior art keywords
binding molecules
modules including
including modified
joining modules
ehd2
Prior art date
Application number
MX2022003507A
Other languages
English (en)
Spanish (es)
Inventor
Roland Kontermann
Oliver Seifert
Original Assignee
Univ Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart filed Critical Univ Stuttgart
Publication of MX2022003507A publication Critical patent/MX2022003507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022003507A 2019-09-25 2020-09-25 Modulos de union que comprenden dominios ehd2 modificados. MX2022003507A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19199639 2019-09-25
PCT/EP2020/077008 WO2021058804A1 (en) 2019-09-25 2020-09-25 Binding modules comprising modified ehd2 domains

Publications (1)

Publication Number Publication Date
MX2022003507A true MX2022003507A (es) 2022-04-25

Family

ID=68109107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003507A MX2022003507A (es) 2019-09-25 2020-09-25 Modulos de union que comprenden dominios ehd2 modificados.

Country Status (9)

Country Link
US (1) US20220372147A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034244A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022550316A (cg-RX-API-DMAC7.html)
KR (1) KR20220071210A (cg-RX-API-DMAC7.html)
CN (1) CN115066275A (cg-RX-API-DMAC7.html)
AU (1) AU2020356407A1 (cg-RX-API-DMAC7.html)
CA (1) CA3155725A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022003507A (cg-RX-API-DMAC7.html)
WO (1) WO2021058804A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4454706A1 (en) 2023-04-24 2024-10-30 Universität Stuttgart Novel egfr binding proteins

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
NZ592611A (en) * 2008-10-10 2013-01-25 Emergent Product Dev Seattle A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release
US20130089554A1 (en) * 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
WO2013075027A2 (en) * 2011-11-17 2013-05-23 Emergent Product Development Seattle, Llc Anti-sil6xr complex binding domains and methods of use
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CA3096486C (en) * 2014-11-14 2023-02-07 The Procter & Gamble Company Silicone compounds
WO2016146818A1 (en) * 2015-03-18 2016-09-22 Universität Stuttgart Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
WO2017106462A1 (en) * 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
KR102469700B1 (ko) * 2016-09-15 2022-11-23 우니베르지테트 스튜트가르트 Her3에 대한 항원 결합 단백질
WO2019179627A1 (en) * 2018-03-22 2019-09-26 Universität Stuttgart Multivalent binding molecules
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
HUE062777T2 (hu) * 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
US11192940B2 (en) * 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
WO2022082217A1 (en) * 2020-10-16 2022-04-21 Eureka Therapeutics, Inc. Compositions for preventing or treating viral and other microbial infections

Also Published As

Publication number Publication date
JP2025081354A (ja) 2025-05-27
CA3155725A1 (en) 2021-04-01
KR20220071210A (ko) 2022-05-31
EP4034244A1 (en) 2022-08-03
AU2020356407A1 (en) 2022-04-07
WO2021058804A1 (en) 2021-04-01
CN115066275A (zh) 2022-09-16
JP2022550316A (ja) 2022-12-01
US20220372147A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
MX2023003630A (es) Aglutinantes de albumina de suero mejorados.
MX2024013316A (es) Aglutinantes de albumina serica mejorados
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
AR124511A2 (es) Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
CY1119928T1 (el) Διμερης λειτουργικη συμπληρωματικοτητα επαγομενη απο διττο αντιγονο
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
CO2018005915A2 (es) Aglutinantes de tnf mejorados
AR077088A1 (es) Proteinas biespecificas de union a antigeno
DOP2018000225A (es) Proteínas de unión triespecíficas y/o trivalentes referencias cruzadas a solicitudes relacionadas
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
MX2015000397A (es) Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos.
MX2020005193A (es) Fusiones de anticuerpo anti-pd-l1 e il-7.
BR112021020999A2 (pt) Polipeptídeos de ligação à clec12a e usos dos mesmos
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
EA201491049A1 (ru) Противораковый слитый белок
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
MX2016001356A (es) Proteina anti-garp y sus usos.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
HRP20220214T1 (hr) Imunomodulacijska sredstva
PE20150023A1 (es) Proteinas de union a antigeno st2
BR112021019915A2 (pt) Proteínas de ligação triespecíficas, métodos e usos dos mesmos
PE20220505A1 (es) Moleculas de union a tigit y pd-1/tigit
CR11059A (es) Novedosas moleculas de anticuerpos y acidos nucleicos que se enlazan con la proteina de tension fungica hsp90
BR112023021034A2 (pt) Proteínas de ligação que reconhecem antígeno ha-2 e usos dos mesmos